Physician profile
Akash Ghai
NPI 1588690440
$5,280.81
in general payments reported to CMS, 2019-2025
35 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $634 · 2021: $1,393 · 2022: $1,468 · 2023: $1,028 · 2024: $441 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $711.47 | 2020-2023 | |
| Amgen INC. | $695.76 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $682.62 | 2020-2024 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $502.93 | 2020-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $339.60 | 2021-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $266.67 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $264.49 | 2021-2024 | Verquvo |
| Bard Peripheral Vascular, INC. | $195.57 | 2022 | |
| Novo Nordisk INC | $194.19 | 2021-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.71 | 2021-2023 | Jardiance |
| Abbott Laboratories | $185.96 | 2021-2025 | Jot Dx, Cardiomems, Confirm Rx |
| Janssen Pharmaceuticals, INC | $156.13 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $152.86 | 2024-2025 | Assure Wcd |
| Philips North America LLC | $106.87 | 2020-2025 | Extended Holter, (Ck7) Extended Holter, (Ck4) Mcot |
| Pfizer INC. | $102.76 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $80.23 | 2020-2021 | |
| Medtronic, INC. | $55.88 | 2021-2023 | Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $32.80 | 2021-2022 | |
| Cardiva Medical, INC. | $31.07 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Itamar Medical INC | $29.23 | 2025 | Watchpatone |
| Kowa Pharmaceuticals America, INC. | $28.54 | 2021-2022 | |
| Endologix LLC | $27.52 | 2022 | |
| Ethicon US, LLC | $27.33 | 2022 | |
| Chiesi USA, INC. | $26.46 | 2021-2022 | |
| Biotronik INC. | $25.72 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $22.02 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $20.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.62 | 2019 | |
| Acacia Pharma INC | $17.89 | 2021 | |
| Medtronic Vascular, INC. | $17.58 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.73 | 2021 | |
| Teleflex LLC | $15.44 | 2022 | |
| Baxter Healthcare | $15.19 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Lilly USA, LLC | $13.84 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Ghai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.